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of cannabis use were not related to schizotypy. Exploratory 
factor analysis of the pooled data from this study and our 
previous report (providing a sample of  1 400 cannabis users) 
suggested a 3-factor solution. These were characterised as a 
psychotic-dysphoric index (factor 1), an expansive index 
(factor 2) and an intoxicated index (factor 3). Schizotypy was 
highly correlated with factors 1 and 3, though not with fac -
 tor 2.  Conclusion: High scoring schizotypes who use canna-
bis are more likely to experience psychotic-dysphoric phe-
nomena and intoxicating effects during and after use. Our 
results confirm and expand the findings reported in our pre-
vious study. They are consistent with the hypothesis that 
cannabis use may be a risk factor for full psychosis in this 
group.  Copyright © 2008 S. Karger AG, Basel
 Introduction
 Cannabis increases both the risk of relapse and the se-
verity of symptoms in individuals already diagnosed as 
having schizophrenia  [1, 2] . According to some research-
ers  [3, 4] , cannabis use also significantly increases the risk 
of developing a psychotic disorder in individuals without 
 Key Words
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 Abstract
 Background: Cannabis use has been identified as a possible 
risk factor for developing schizophrenia. In a previous paper 
we reported preliminary evidence that cannabis use increas-
es the likelihood of psychosis-like experiences in non-clini-
cal respondents who scored highly on a measure of schizo-
typy. We now present findings from pooled data from 3 new 
follow-up studies comprising a sample of 477 respondents, 
of whom 332 reported using cannabis at least once.  Sam-
pling and Methods: As in our previous study, the psycho-
logical effects of cannabis were assessed with the Cannabis 
Experiences Questionnaire, from which 3 subscales can be 
derived; encompassing pleasurable experiences, psychosis-
like experiences and after-effects. The respondents also 
completed the brief Schizotypal Personality Questionnaire. 
 Results: Cannabis use was reported by 70% of the sample. 
Use per se was not significantly related to schizotypy. How-
ever, high scoring schizotypes were more likely to report 
both psychosis-like experiences and unpleasant after-ef-
fects associated with cannabis use. The pleasurable effects 
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any history of illness. It is nevertheless methodologically 
difficult to establish whether people who are prone to 
psychosis are drawn to cannabis use (an association mod-
el), or whether cannabis use truly increases the incidence 
of psychotic experiences (a causal model)  [3–5] . However, 
data from 3 recently reported studies favour the latter 
model, since early cannabis use, predating any self-re-
ported psychosis-like symptoms, appears to be a risk fac-
tor for later psychosis  [6–8] .
 To further explore the relationship between cannabis 
use and psychosis vulnerability, researchers have turned 
to the use of self-report measures of schizotypy in non-
clinical samples as an index of psychosis proneness. Re-
cent studies have, for example, reported that cannabis us-
ers have higher schizotypy scores than non-users  [9–12] 
and that current users have higher schizotypy scores than 
past users  [13] . Whilst of some interest, such studies are 
generally limited by their failure to record the rich and 
varied phenomenological experiences of respondents. 
Yet cannabis use has long been associated with an in-
crease in the reporting of ‘psychosis-like’ experiences for 
certain individuals  [14, 15] and Verdoux et al.  [16] showed 
that psychosis vulnerability and cannabis use were inde-
pendently associated with unusual perceptual experienc-
es. More recently, Henquet et al.  [17] have reported that 
early psychosis-like experiences increase the likelihood 
of subsequent ‘psychotic states’ following cannabis use, 
an effect possibly mediated by genetic differences in the 
sensitivity to the principal active ingredient   9-tetrahy-
drocannabinol  [18] .
 In 2003, we began to work on the development of a 
self-report questionnaire that would enable cannabis us-
ers to quickly record psychological (and some somatic) 
effects experienced both as they smoked cannabis and for 
some time after use. The upshot was the Cannabis Expe-
riences Questionnaire (CEQ); the substantive part of 
which has remained unchanged since its inception, com-
prising checklists of concurrent and after-effect experi-
ences that respondents can endorse using a 5-point Likert 
scale. Previously, we reported preliminary findings of re-
lationships between high schizotypy and negative (psy-
chosis-like) and amotivational-syndrome-like after-ef-
fect experiences in this journal  [19] . Since then 3 new in-
dependent samples have completed both the CEQ and the 
brief Schizotypal Personality Questionnaire (SPQB)  [20] , 
and we now report findings based on the pooled data 
from these. As in our pilot study, we expected to find as-
sociations between higher schizotypy scores and an in-
creased reporting of negative and after-effect experiences 
of cannabis.
 Method
 Three ‘new’ independent samples form our pooled cohort; as 
follows:
 (1) a Manchester student sample (n = 219; 80 males and 139 fe-
males);
 (2) a Dutch young person sample (n = 165; 104 males and 61 fe-
males);
 (3) a test-retest sample comprising a mix of UK students and non-
student adults (n = 93; 32 males and 61 females).
 A range of recruitment procedures was employed in order to 
optimise the sample sizes in each instance. For sample 1, notices 
were posted around the university campus inviting interested in-
dividuals to contact a researcher for further information about 
the study. A participant information sheet was then provided, 
along with copies of the CEQ and SPQB. The respondents were 
asked to complete both as fully and honestly as possible in their 
own time. An anonymisation procedure ensured that the respon-
dents were identifiable only by a PIN and password. Completed 
questionnaires were to be returned to a labelled postbox placed in 
a communal area of the campus or to be posted to the researcher 
in a pre-paid envelope. Sample 2 was recruited predominantly by 
college email. Students received a ‘pop-up’ message inviting them 
to visit a website where they could learn more about the study and 
complete electronic versions of the 2 questionnaires. Additional 
non-student respondents were recruited by asking the partici-
pants to invite friends and siblings to complete hard copies of each 
questionnaire to be mailed back to the study coordinator. Once 
again, the use of a PIN and password ensured respondent ano-
nymity. Sample 3 was similarly recruited with a mix of electronic 
contact of students and word-of-mouth recruitment of non-stu-
dent adults ( 1 21 years of age) through various social network 
groupings including a mothers and babies group, a film/book club 
and a hiking club. Summary demographic information about 
these samples is provided in  table 1 . Overall, our pooled cohort 
comprised 477 respondents, of whom 332 (70%) had at least 1 ex-
perience of using cannabis. The participants did not receive any 
financial compensation for taking part in the study.
 Measures
 Schizotypy. The participants completed the SPQB, a 22-item 
questionnaire consisting of the most reliable items taken from the 
longer Schizotypal Personality Questionnaire  [21] . The question-
naire was presented as a personality assessment with the follow-
ing instructions: ‘Please answer each item by ticking one of the 
two boxes (Yes or No) to the right of each statement/question. An-
swer all items even if unsure of your answer. When you have fin-
ished, check over each one again to make sure you have indicated 
Y or N to each statement/question.’ The SPQB provides a total 
score and scores on 3 subscales: ‘disorganized’ (SPQB-D), ‘cogni-
tive-perceptual’ (SPQB-CP) and ‘interpersonal’ (SPQB-I).
 Cannabis Experiences. Items were identified for inclusion in 
early versions of the CEQ through a combination of literature 
search, perusal of journal and web-based descriptions of cannabis 
intoxication/psychosis  [22–24] and personal qualitative accounts 
from cannabis users. Subsequent pilot testing prompted minor 
changes both to the list of items to be included and the means of 
endorsing these items. The current CEQ comprises 2 checklists to 
record concurrent (43 items) and after-effects (12 items) associ-
ated with cannabis use that the respondent can endorse using a 
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5-point Likert scale ranging from ‘hardly ever or never applies’  [1] 
to ‘almost always or always applies’  [5] .  The concurrent experi-
ences checklist effectively merges 2 clusters of experiences which 
we have previously referred to as positive (pleasurable) and nega-
tive (psychosis-like) experiences. Examples of positive items in-
clude ‘having enhanced perceptual awareness’ and ‘being able to 
understand the world better’. The cumulative scores on this sub-
scale can range from 18 to 90. The negative concurrent items 
chiefly comprise psychological experiences that might preferably 
be avoided, ‘feeling paranoid’ and ‘fearful of going mad’ being 2 
such examples. For this subscale the scores can range from 25 to 
125. The after-effects subscale attempts to quantify the conse-
quences of cannabis post-use and consists of items associated with 
the ‘amotivational syndrome’ commonly reported in habitual us-
ers  [25] , e.g. ‘not wanting to do anything’ or ‘feeling generally 
slowed down’. The scores on this scale could range from 12 to 60. 
The instructions relating to the completion of each checklist were 
as follows:
 Concurrent experiences: ‘How often do you have/have you 
had these experiences while  smoking cannabis?’
 After-effects: ‘How often have you had/did you have these ex-
periences  after the initial effects of cannabis had worn off but 
which you feel are nevertheless directly related to recent use of 
cannabis?’
 Cannabis Use. The participants were asked how often (every 
day, more than once a week, about once a week, about once a 
month, a few times each year, about once a year, only once or 
twice, never) and when they smoked cannabis (during the morn-
ing, during the day, during the evening, frequently during the day 
and night). Information about other drugs used for recreational 
purposes was also sought in samples 1 and 2 (though not for sam-
ple 3). However, samples 2 and 3 were additionally asked a series 
of questions about the preferred strength (of cannabis), number 
of times ever used and weekly expenditure (on cannabis), which 
together provide a proxy of cannabis consumption.
 Procedure
 We should emphasise that as part of the questionnaire devel-
opment, the samples described above actually completed slightly 
different versions of the CEQ: the student sample completed the 
original version  [19] save for the inclusion of a structured section 
on other drug use; the Dutch sample completed a translated 
Dutch version which additionally attempted to quantify the vol-
ume of consumption of cannabis, and the test-retest sample com-
pleted a version that also assessed the consumption of cannabis 
but not of other recreational drugs. However, it is important to 
note that in all cases, the substantive Likert scale checklists of 
cannabis experiences were unchanged.
 Data analysis was performed using SPSS (version 12.0.1). Non-
normally distributed data were transformed as appropriate, and 
differences between groups were tested with t tests or analysis of 
variance. Within groups, Pearson’s coefficient was used to estab-
lish the size of correlation. In all cases the 0.05 level of significance 
(2-tailed) was used. The study had full ethical approval (both in 
Manchester, UK, and Deventer, the Netherlands).
 Results
 Seventy percent of our pooled cohort reported having 
used cannabis at least once, and from samples 2 and 3 it 
would appear that the majority [114/185 (62%)] are cur-
rent users. The frequency of use for current and past users 
combined [310/332 complete data sets] was recoded into 
4 bands as follows: a few times each week, 16% (50/310); a 
few times each month, 38% (117/310); a few times each 
year, 40% (126/310); less than once a year, 5.5% (17/310). 
There were no significant gender differences in the rates 
of cannabis use. The modal age for first use was 15
(mean = 15 years 5 months; SD = 2.08), although  1 5% had 
tried cannabis by the age of 12. As the mean age at re-
cruitment was 22 years 5 months (SD = 5.68), most re-
spondents had been using cannabis at least intermittent-
ly for about 7 years at the time of assessment. Most users 
consumed cannabis in the evenings (41%) with friends 
(67%). However, from samples 2 and 3 it appears that
the expenditure on cannabis is modest: more than half 
 Table 1. Sample demographics








 Manchester student sample  219  22.8 80:139  yes: 147 (67)
 no: 72 (33) 
 not recorded  May 2004 
 Dutch young people sample  165  20.8  104:61  yes: 120 (73)
 no: 45 (27) 
 74 current
 46 past 
 2006 
 Test-retest sample 93  22.7 32:61  yes: 65 (70)
 no: 28 (30) 
 40 current
 25 past 
 July 2006 
 Combined cohort  477  22.1  216 M
 261 F 
 yes: 332 (70)
 no: 145 (30) 
 Figures in parentheses are percentages. 
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(56.5%) spend GBP 2.50 (EUR 4) per week or less on the 
drug.
 From samples 1 and 2 it is apparent that for slightly 
more than half (139/267) of the cannabis users, cannabis 
was the only (illegal) drug used (although 76% consumed 
alcohol on at least an occasional basis). For the remainder 
(n = 128) the number of other illicit drugs used varied be-
tween 1 (41% of the sample) and 10 (0.7% of the sample). 
The drugs of choice (listed according to the frequency of 
reporting) included ecstasy (26%), magic mushrooms 
(25%), amphetamine (17%), cocaine (17%), LSD (13%), 
poppers (7%) and ketamine (4%). The drugs which were 
used by  ! 2% of the participants included solvents, GHB, 
nutmeg, benzodiazepines, MDA, opiates and barbiturates. 
Ten respondents who reported using other drugs (LSD, co-
caine and morphine) but not cannabis were included in the 
analyses reported below as non-cannabis users. There 
were no significant differences in any demographic mea-
sures between cannabis-only users and poly-users, with 
the exception that the latter group were more likely to be 
frequent cannabis users (  2  = 23.06, p  ! 0.01).
 The SPQB means and SD (in brackets) for the pooled 
cohort were as follows: SPQB-CP: 3.63 (3.97), SPQB-I: 
4.01 (3.92), SPQB-D: 2.48 (2.90) and for the SPQB total 
score 10.13 (10.22). The SPQB total scores required loga-
rithmic transformation and each of the subscales needed 
inverse transformation prior to statistical analysis. There 
were no significant differences between those who re-
ported having used cannabis and those who had not on 
the SPQB total or any of the SPQB subscales (all p  1 0.05). 
However, amongst users, greater regularity of consump-
tion was associated with both higher SPQB subscale 
scores (SPQB-CP: F = 8.65, d.f. = 3, 305, p  ! 0.001; SPQB-
I: F = 6.61, d.f. = 3, 305, p  ! 0.001; SPQB-D: F = 5.26,
d.f. = 3, 305, p = 0.001, and SPQB total: F = 7.66, d.f. =
3, 305, p  ! 0.001). Age at first use was not correlated sig-
nificantly with any of the SPQB measures. Moreover, 
there were no significant differences on any of the SPQB 
measures between cannabis-only users and poly-users.
 Relationship between SPQB Scores and CEQ Subscales
 Amongst the cannabis users (n = 332; 70%) the means 
(with SD in brackets) for the subscales from the CEQ were 
as follows: pleasurable experiences = 42.26, (12.25), psy-
chosis-like experiences = 43.99 (13.88) and after-effects = 
22.87 (9.16). [These bear comparison with those described 
in our pilot study of 39.94 (9.94) for pleasurable experi-
ences, 43.12 (12.98) for psychosis-like experiences and 
22.71 (9.31) for after-effects.] In each case, the distribu-
tion of data was approximately normal. Bivariate corre-
lational analyses were performed in line with the stated 
hypotheses. These indicated significant correlations be-
tween the psychosis-like experiences subscale and the 
SPQB-D subscale (r = 0.320, p  ! 0.001), the SPQB-CP 
subscale (r = 0.327, p  ! 0.001), the SPQB-I subscale (r = 
0.299, p  ! 0.001) and the SPQB total score (r = 0.333, p  ! 
0.001). The after-effects subscale was also correlated with 
the SPQB-D subscale (r = 0.315, p  ! 0.001), the SPQB-CP 
subscale (r = 0.293, p  ! 0.001), the SPQB-I subscale (r = 
0.265, p  ! 0.001) and the SPQB total score (r = 0.306, p  ! 
0.001). All significant correlations would have survived a 
Bonferroni-corrected   level of 0.0125. The pleasurable 
experiences subscale was not significantly correlated 
with any SPQB scores. An almost identical pattern of cor-
relations (between the SPQB and CEQ scales) was appar-
ent when cannabis-only and poly-users were considered 
separately, indicating that our decision to pool data from 
these 2 subgroups was justified.
 Exploratory Factor Analysis of CEQ Checklist Data
 We combined the data set from this investigation with 
that from the pilot study reported on previously to provide 
a single merged file comprising 614 respondents, of whom 
431 were positive for cannabis use. (Pooling generated a 
sample to meet the requirements of exploratory factor 
analysis). Current and after-effect data were also pooled (as 
cannabis-related experiences) and subjected to principal 
component analysis with Varimax rotation. Inspection of 
the resultant variance table and scree plot combined sug-
gested a 3-factor solution. Inspection of the rotated com-
ponent matrix indicated that factor 1 (23% of total vari-
ance) represented a psychotic-dysphoric dimension which 
overlapped with our psychosis-like scale but also included 
several affective/discomfort items. Factor 2 (11% of vari-
ance) comprised items from across the CEQ and could be 
characterised as an ‘intoxicated’ dimension. Factor 3 (6% 
of variance) exclusively covered selective items from the 
pleasurable experiences scale and could be characterised 
as an ‘expansive-positive’ index. In view of the exploratory 
nature of this analysis, in  table 2 we identify only the items 
making a unique factor loading of at least 0.5.
 The psychotic-dysphoric scale is of interest in the con-
text of this report as the 14 items ‘loading’ on it (at least 
0.5) are those that might reasonably be expected from any 
psychoto-mimetic and dysphoric effects of cannabis. 
These items were subject to a reliability analysis generat-
ing a Cronbach’s   coefficient of 0.908, without any item 
appearing to undermine this high level of internal reli-
ability. A further scale was therefore generated based on 
the cumulative score of just these 14 items; called the psy-
 High Schizotypy Predicts Cannabis-
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chotic-dysphoric score. The bivariate correlations be-
tween this score (inverse transformed) and the trans-
formed SPQB scores were as follows: with SPQB-CP, r = 
0.345; with SPQB-I, r = 0.243; with SPQB-D, r = 0.311, 
and with SPQB -total, r = 0.350 (all significant at p  ! 0.001 
with n minimum  = 388). However, a high psychotic-dys-
phoric score per se was not predicted by frequency of use 
(F  ! 1, d.f. = 3, 305, n.s.). Schizotypy was also correlated 
more modestly with the intoxicated factor score (which 
evinced a Cronbach   of 0.881): with SPQB-CP, r = 0.208; 
with SPQB-I, r = 0.182; with SPQB-D, r = 0.251, and with 
SPQB total, r = 0.300 (also all significant at p  ! 0.001 with 
n minimum  = 388). However, as with the psychotic-dysphor-
ic score, the intoxicated factor score was not predicted by 
frequency of use (F  ! 1, d.f. = 3, 305, n.s.). The expansive 
factor score also showed good internal reliability (Cron-
bach’s   = 0.877) but did not correlate significantly with 
any of the schizotypy measures.
 Present versus Past Cannabis Users
 The individuals in samples 2 and 3 could indicate 
whether they were current (n = 114) or past (n = 71) users 
of cannabis. These groups did not differ significantly in 
terms of frequency of use, nor on any SPQB measure, but 
there was a highly significant interaction between group 
and cannabis experiences (F = 10.73, d.f. = 1, 178, p = 
0.001), with current users reporting more positive and 
fewer negative experiences than past users.
 Discussion
 The main finding from this investigation is that we 
have been able to replicate the results from our pilot study 
 [19] to show significant correlations between schizotypy 
and certain types of negative concurrent and after-effect 
experiences associated with cannabis use, though not 
with positive-expansive experiences related to the drug. 
 Table 2. Rotated component matrix of concurrent and after-effects
 Factor 1 ‘psychotic-dysphoric’
 (Cronbach’s   = 0.907) 
 Factor 2 ‘intoxicated’
 (Cronbach’s   = 0.881) 
 Factor  3 ‘expansive’
 (Cronbach’s  = 0.877) 
 Feeling anxious (0.723)  Feeling generally slowed down 
(AE) (0.804) 
 Feeling more creative (0.736) 
 Fearful that you are going mad 
(0.669) 
 Do not want to do anything 
(AE) (0.779) 
 Full of plans (0.709) 
 Suspicious without reason (AE) 
(0.664) 
 Feeling  that your thinking has 
been slowed down (AE) (0.742) 
 Full of ideas (0.705) 
 Feeling like you no longer know 
yourself (0.656) 
 Cannot concentrate (AE) 
(0.678) 
 Ecstatic (0.688) 
 Paranoid without reason (AE) 
(0.655) 
 Have reduced attention (AE) 
(0.665) 
 Able to understand the world 
better (0.654) 
 Paranoid (0.651)  Loss of motivation (AE) (0.653)  Energized (0.648) 
 Nervy (0.634)  Slowing of time (AE) (0.592)  Enhanced perceptual awareness 
(0.640) 
 Depressed (0.580)  Sleepy (0.525)  Rapid flow of thoughts (0.565) 
 Fearful (0.572)  Lethargic (0.515)  Looking for excitement (0.538) 
 Hearing things others do not hear 
(auditory hallucinations) (0.570) 
 Feeling excited (0.519) 
 Things not feeling right on your 
skin (0.567) 
 Feeling like you could do
anything (0.511) 
 Disturbed in your thinking (0.563)  Powerful (0.509) 
 Feeling depersonalised (AE) 
(0.528) 
 Sad (0.519) 
 Factor loadings of 0.5 or larger are shown in descending order of magnitude. AE = Item from the after-effect 
checklist. All other items are from the positive/negative concurrent experiences checklist. 
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Our main hypotheses have therefore been supported in a 
much larger pooled cohort. Moreover, the ‘stepped’ mod-
ifications to the CEQ made since our initial study do not 
seem to have undermined its ability to ‘capture’ the core 
psychological sequalae of cannabis use.
 As in our pilot study, reported cannabis use was com-
paratively high (overall 70%, compared with 72% in our 
pilot study). The heterogeneity and size of our pooled co-
hort suggest that our previous findings could not simply 
be attributed to the vagaries of student life in Manchester, 
UK. Our present cohort additionally comprised 150 
young Dutch people and at least 50 non-student UK 
adults. It would thus seem that cannabis use remains 
widespread despite recent media campaigns (in the UK 
at least) to expose its attendant dangers. On the other 
hand, only 16% (50/310) reported using cannabis more 
frequently than once a week, and almost half the sample 
(46%; 143/310) indicated using it once a month or less. 
The expenditure per week on acquiring cannabis was 
also typically modest (EUR  ! 4), reinforcing the view that 
many of our respondents might be considered occasional 
rather than habitual users. For them, smoking cannabis 
would seem, for the most part, an innocuous and social-
ly accepted activity to be enjoyed with friends. The failure 
to find a trend of increased negative experiences with in-
creased frequency of use is also of interest in this context: 
Such experiences may be important in the psychosis 
proneness debate which we revisit below, but they are rel-
atively uncommon and clearly not simply a consequence 
of greater exposure to the drug.
 In common with our pilot study but contrary to previ-
ous research  [9–12] we did not find that cannabis users 
had significantly higher schizotypy scores than non-us-
ers. However, reported use was higher (70%) than in all 
other studies that  have found an association (typically 
 ! 30% usage). Moreover, amongst users, greater frequen-
cy of use  is clearly associated with higher schizotypy. So 
despite the comparatively high rate of cannabis consump-
tion in our samples, the increased reporting of psychosis-
like experiences in cannabis users with high schizotypy 
scores broadly supports the findings of others  [16, 17] .
 The question of whether respondents are current or 
past users may also be germane to this matter. Of the 185 
individuals responding to this question (only samples 2 
and 3 were asked) the current users reported more posi-
tive and fewer negative experiences than the former users 
(the levels of after-effects were similar in both groups). 
One interpretation of this interaction is that people con-
tinue to use cannabis because they enjoy its expansive ef-
fects. An alternative explanation is that some people stop 
using cannabis because they do not like the elevated lev-
els of negative psychotic-like effects. Invited written com-
ments from a number of past users tend to support the 
latter explanation. One wrote: ‘I used to smoke cannabis 
regularly until one occasion when a friend and me (sic) 
shared some ‘‘weed’’ and I felt uneasy, agitated, paranoid 
… that I was going mad … for several days after …’
 She understandably found this experience frightening 
and has remained abstinent ever since.
 Apart from the observation that poly-drug users also 
consume cannabis more frequently, there were no other 
clear-cut differences between this group and cannabis-
only users, either in relation to basic demographics or 
schizotypy, or in the pattern of interrelationships be-
tween the CEQ and SPQB measures. This finding is reas-
suring but not altogether surprising in view of the ex-
plicit instructions heading each of the CEQ checklists, 
which ask the respondent to endorse only effects related 
to concurrent or recent cannabis use.
 The exploratory factor analysis of current and after-
effect experiences provides an interesting alternative way 
of interpreting CEQ responses. This analysis was con-
ducted on the total merged cohort from both the present 
and pilot studies to provide a suitably large sample of 431 
individuals positive for cannabis use. We deemed a 3-fac-
tor solution optimal because, although several other fac-
tors had eigenvalues of  1 1, these tended to have only 1 or 
2 loading items and, critically, were to the right of the 
scree plot dogleg. To further explore the factors we em-
ployed a conservative criterion factor loading of 0.5, 
which identified 14 items loading on factor 1 (psychotic-
dysphoric), 9 loading on factor 2 (intoxicated) and 12 
loading on factor 3 (expansive), all of which showed high 
internal reliability ( table 2 ). Predictably, factor 3 com-
prised items exclusively drawn from (positive) current 
experiences, whereas items loading on factors 1 and 2 en-
compassed both current and after-effect experiences. If a 
researcher is hoping to quantify typical concurrent and 
after-effect cannabis experiences, the original scales 
(positive, negative and after-effects) may suffice. How-
ever, if the researcher intends to identify individuals 
evincing the most pathological pattern of cannabis expe-
riences, s/he may prefer to focus on items contributing to 
factor 1. We note that of all the summary scores drawn 
from the CEQ in our final pooled data set, the psychotic-
dysphoric score generated the most robust correlations 
with schizotypy and may represent the best index of psy-
chosis vulnerability in cannabis users.
 As in our pilot study, a limitation of the current study 
is that the participants were not screened for the presence 
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(or family history) of psychiatric illnesses: either might 
reasonably be predicted to be associated with higher neg-
ative and after-effect scores on the CEQ, but our ethical 
approval did not extend to recording this information. 
Similarly, in terms of psychopathological traits, we have 
thus far deliberately restricted our interest to the obvious 
candidate of schizotypy. Other measures also now merit 
attention, some of which correlate closely with schizo-
typy (such as delusion and hallucination proneness  [26, 
27] ) and others which correlate less closely (such as trait 
anxiety  [28] ) or that may be independent (such as sensa-
tion seeking  [29] ). A further procedural concern is that 
the overall structure of the CEQ (though not the vital 
checklists) varied somewhat from sample to sample, as 
we sought to refine and improve the effectiveness of the 
self-report measure as a psychometric tool. A final caveat 
is that some participants may have mistakenly indicated 
responses on the SPQB that actually reflected their expe-
riences with cannabis: for example endorsing SPQB item 
7 about ‘needing to be on (my) guard even with friends’ 
because they sometimes ‘felt apprehensive of others’ 
when using cannabis. This seems unlikely in view of the 
specific instructions relating to the completion of each 
questionnaire (coupled with the explicit descriptions of 
the SPQB and CEQ as a general personality measure and 
a drug usage/reaction measure, respectively, in the infor-
mation sheet) but cannot be entirely ruled out. Addition-
al instructions regarding the completion of the SPQB 
may be appropriate in subsequent studies.
 Our findings lend weight to our earlier suggestion that 
individuals who have high schizotypy scores and who re-
port psychotic-like responses to cannabis may represent 
a group at elevated risk for psychosis. However, it is im-
portant to remember that this study is essentially corre-
lational in nature. Most cannabis users seem able to use 
the drug with relative impunity, and some who sense 
danger signs may decide to stop. Moreover, it is widely 
acknowledged that most individuals with high levels of 
trait schizotypy do not ‘convert’ to full-blown psychosis 
 [10] . Our findings merely suggest that high schizotypes 
who use cannabis are more likely to report psychotic and 
dysphoric experiences related to its consumption, and 
such individuals may be at increased risk of developing 
psychosis in the future.   9-Tetrahydrocannabinol, the 
principal active ingredient in cannabis  [30] , binds to can-
nabinoid receptors localized in the prefrontal cortex, bas-
al ganglia and hippocampus  [31] , where it has a dopamine 
agonist action  [32, 33] . The heightened sensitivity of do-
pamine systems observed in acute schizophrenia  [34] 
may also be present to some degree along the psychosis 
continuum [e.g.  35 ].   9-Tetrahydrocannabinol given to 
healthy volunteers is known to produce psychotic-like 
symptoms when administered intravenously  [36] or to 
produce a ‘psychosis prodrome state’ following oral ad-
ministration  [37] . An increased sensitivity to it  [17] would 
explain why high scoring schizotypes who use cannabis 
are more likely to have psychosis-like experiences and 
pronounced after-effects than their low scoring counter-
parts. However, a large-scale longitudinal study would be 
required in order to establish whether such individuals 
are more likely than others to develop a psychotic illness 
at some point in the future.
 The CEQ has been revised several times since the in-
ception of this research programme. The current version 
includes the same concurrent and after-effect checklists 
as we used in our previously reported pilot study (save for 
minor changes to the wording of items) but additionally 
records information about the pattern and history of use/
consumption and other drug use. All told, it has now 
been used successfully in 4 separate studies comprising 
 1 600 respondents. It appears to be an acceptable and use-
ful instrument which is quick and easy to complete and 
which generates reliable quantitative data capturing most 
of the frequently reported subjective experiences linked 
to cannabis use. We are happy to make a copy of this 
questionnaire available to interested parties on request.
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